medicalxpress - A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.
#healthcare #publichealth #governmentpolicy #biotech #medicaldevices #oncology
Thursday, February 26, 2026, 7:24 pm / permalink 19851 / 7 stories in 18 days
Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...
#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #drugdevelopment
Thursday, February 26, 2026, 7:23 am / permalink 19788 / 12 stories in 18 days
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 16.5 hours
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 17.5 hours
Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 19.5 hours
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 20.5 hours
FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 32.5 hours
HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 45.5 hours
Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 48.5 hours
Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 49.5 hours
Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 54.5 hours
AI improves UK breast-screening detection by about 10% 5 stories in 54.5 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: